A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Clinical trial NCT00671788 · COMPLETED

Trial details

NCT number: NCT00671788
Sponsor: Gynecologic Oncology Group
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Start date: 2008-06-01
Primary completion: 2010-12-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.